Su-Yeon Yu

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/233530/publications.pdf Version: 2024-02-01



SUL-YEON YU

#	Article	IF	CITATIONS
1	Effects of acute renal failure induced by uranyl nitrate on the pharmacokinetics of intravenous theophylline in rats: the role of CYP2E1 induction in 1,3-dimethyluric acid formation. Journal of Pharmacy and Pharmacology, 2010, 54, 1687-1692.	2.4	25
2	Clinical efficacy and safety of interleukin-6 receptor antagonists (tocilizumab and sarilumab) in patients with COVID-19: a systematic review and meta-analysis. Emerging Microbes and Infections, 2022, 11, 1154-1165.	6.5	25
3	Dose-Independent Pharmacokinetics of a New Reversible Proton Pump Inhibitor, KR-60436, after Intravenous and Oral Administration to Rats: Gastrointestinal First-Pass Effect. Journal of Pharmaceutical Sciences, 2003, 92, 1592-1603.	3.3	23
4	Revised Korean Society of Infectious Diseases/National Evidence-based Healthcarea Collaborating Agency Guidelines on the Treatment of Patients with COVID-19. Infection and Chemotherapy, 2021, 53, 166.	2.3	21
5	Comparing proton pump inhibitors with histamin-2 receptor blockers regarding the risk of osteoporotic fractures: a nested case-control study of more than 350,000 Korean patients with GERD and peptic ulcer disease. BMC Geriatrics, 2020, 20, 407.	2.7	17
6	Cost-Effectiveness of Nationwide Opportunistic Screening Program for Dementia in South Korea. Journal of Alzheimer's Disease, 2015, 44, 195-204.	2.6	16
7	Health technology assessment in sub-Saharan Africa: a descriptive analysis and narrative synthesis. Cost Effectiveness and Resource Allocation, 2021, 19, 39.	1.5	16
8	New Anti-Rebate Legislation in South Korea. Applied Health Economics and Health Policy, 2013, 11, 311-318.	2.1	14
9	Supervised Physical Rehabilitation in the Treatment of Patients with Advanced Cancer: a Systematic Review and Meta-analysis. Journal of Korean Medical Science, 2020, 35, e242.	2.5	9
10	Consumption of medicines used for gastric acid-related disorders in Australia and South Korea: a cross-country comparison. European Journal of Clinical Pharmacology, 2020, 76, 547-555.	1.9	8
11	Korean Society of Infectious Diseases/National Evidence-based Healthcare Collaborating Agency Recommendations for Anti-SARS-CoV-2 Monoclonal Antibody Treatment of Patients with COVID-19. Infection and Chemotherapy, 2021, 53, 395.	2.3	6
12	Research governance authorisation: the next frontier. Australian Health Review, 2021, 45, 389-392.	1.1	4
13	Utilization Patterns of Coagulation Factor Consumption for Patients with Hemophilia. Journal of Korean Medical Science, 2016, 31, 33.	2.5	2
14	HPLC ANALYSIS OF A NEW REVERSIBLE PROTON PUMP INHIBITOR, A DIHYDROPYRROLOQUINOLINE DERIVATIVE, IN PLASMA, URINE, AND TISSUE HOMOGENATES. Journal of Liquid Chromatography and Related Technologies, 2002, 25, 2687-2694.	1.0	1
15	Efficacy and Safety of COVID-19 Vaccines in Children Aged 5 to 11 Years: A Systematic Review. Pediatric Infection and Vaccine, 2022, 29, 28.	0.4	1
16	Diagnostic accuracy of prostate-specific antigen below 4 ng/mL as a cutoff for diagnosing prostate cancer in a hospital setting: A systematic review and meta-analysis. Investigative and Clinical Urology, 2022, 63, 251.	2.0	1
17	Survival of advanced melanoma patients treated with immunotherapy and targeted therapy: A realâ€world study. Pharmacoepidemiology and Drug Safety, 2021, 30, 1371-1379.	1.9	0